Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Cardia Bioplastics's Sloan Ratio for the quarter that ended in Dec. 2023 was -30.16%.
Warning Sign:
When sloan ratio (-29.07)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.
As of Dec. 2023, Cardia Bioplastics has a Sloan Ratio of -30.16%, indicating earnings are more likely to be made up of accruals.
Cardia Bioplastics Sloan Ratio % Historical Data
The historical data trend for Cardia Bioplastics's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cardia Bioplastics's Sloan Ratio %
For the Packaging & Containers subindustry, Cardia Bioplastics's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardia Bioplastics's Sloan Ratio % Distribution in the Packaging & Containers Industry
For the Packaging & Containers industry and Consumer Cyclical sector, Cardia Bioplastics's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Cardia Bioplastics's Sloan Ratio % falls into.
Cardia Bioplastics Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Cardia Bioplastics's Sloan Ratio for the fiscal year that ended in Jun. 2023 is calculated as
For company reported semi-annually, GuruFocus uses latest two semi-annual data as the TTM data.
Cardia Bioplastics's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was -4.269 (Jun. 2023 ) + -3.033 (Dec. 2023 ) = A$-7.30 Mil.
Cardia Bioplastics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was 0.881 (Jun. 2023 ) + -0.386 (Dec. 2023 ) = A$0.50 Mil.
Cardia Bioplastics's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was -0.267 (Jun. 2023 ) + -0.23 (Dec. 2023 ) = A$-0.50 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardia Bioplastics (ASX:CNN) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Dec. 2023, Cardia Bioplastics has a Sloan Ratio of -30.16%, indicating earnings are more likely to be made up of accruals.
Cardia Bioplastics Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Cardia Bioplastics's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
SECOS Group Ltd is an Australian developer and manufacturer of sustainable packaging materials. . Business operating segment includes the manufacture and distribution of polyethylene films, renewable resource-based resins, and finished products. It supplies proprietary biodegradable resins, packaging products cast films to a customer base spread globally.SECOS Global Application Development Centre is in Australia. Product Development Centre and manufacturing plant for resins and finished products in China and resins plant in Malaysia. It also has manufacturing plants for cast films in Malaysia. It conducts sales via geographical regions that include Australia, Asia, America, Europe, and Africa. Asia generates maximum revenue for the company.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ASX:CNN has been successfully added to your 